aprott
Eli Lilly (NYSE:LLY) shares dropped on Thursday after lowering its full-year outlook amid a decision by CVS Health (NYSE:CVS) to limit access to the company’s popular weight loss drug, Zepbound, in favor of Novo Nordisk’s (NVO) rival drug, Wegovy.
In